Published by Iain Gilbert on 27th October 2026
(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that Enhertu has been approved in the European Union as an adjuvant treatment for adults with HER2‑positive early breast cancer who still have signs of invasive disease after initial chemotherapy and targeted therapy.
URL: http://www.digitallook.com/dl/news/story/36308171/...